Showing 1,001 - 1,020 results of 105,158 for search '(( 2 de decrease ) OR ( 5 ((((fold decrease) OR (point decrease))) OR (a decrease)) ))', query time: 1.55s Refine Results
  1. 1001
  2. 1002

    Significant decrease of SMAD4 protein in DBA iPSCs. by Jingping Ge (636557)

    Published 2015
    “…A) Slight decrease of mRNA level of <i>SMAD4</i> in the DBA iPSCs with <i>RPS19</i> or <i>RPL5</i> mutations. …”
  3. 1003
  4. 1004

    Decreased biomechanical stability of bones from <i>Col1a1-Krm2</i> transgenic mice. by Jochen Schulze (365258)

    Published 2013
    “…(D) Cortical thickness (C.Th.) and bone mineral density (vBMD) are decreased in <i>Col1a1-Krm2</i> transgenic mice compared to wildtype littermates. …”
  5. 1005
  6. 1006
  7. 1007

    A R13A point mutation in C4 attenuates CLCuMuV infection. by Asigul Ismayil (5698946)

    Published 2018
    “…<b>(C)</b> The mutant CLCuMuV carrying C4<sup>R13A</sup> (CLCuMuV-C4<sup>R13A</sup>), which contains a R13A mutation in <i>C4</i>, showed the decreased viral symptom compared to wild type CLCuMuV. …”
  8. 1008
  9. 1009

    Tun increases mitochondrial fission, inflammatory cell infiltration, and decreased ER-mitochondria interaction in neonatal rat lungs. by Kirkwood A. Pritchard Jr. (13449794)

    Published 2022
    “…The decreased expressions of GRP75 (0.5±0.2-fold, p = 0.006767, n = 5) and acyl-CoA synthetase long-chain family member 4 (ASCL4; 0.3±0.1-fold, p<0.001, n = 5) indicate a decreased interaction between ER and mitochondria by Tun. …”
  10. 1010
  11. 1011
  12. 1012
  13. 1013

    Nitrile in the Hole: Discovery of a Small Auxiliary Pocket in Neuronal Nitric Oxide Synthase Leading to the Development of Potent and Selective 2‑Aminoquinoline Inhibitors by Maris A. Cinelli (1309419)

    Published 2017
    “…We previously developed a class of membrane-permeable 2-aminoquinoline inhibitors and later rearranged the scaffold to decrease off-target binding. …”
  14. 1014
  15. 1015

    S5 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    “…Cost-based pricing models are discussed as a possibility for cost containment. This study focuses on two drugs, pembrolizumab (Keytruda) and daratumumab (Darzalex), to explore the potential effect of indication broadening on the estimated price when using the cost-based pricing (CBP) model proposed by Uyl-de Groot and Löwenberg (2018).…”
  16. 1016
  17. 1017
  18. 1018
  19. 1019
  20. 1020